Contact Us

Impact Analysis of Covid-19

The complete version of the Report will include the impact of the COVID-19, and anticipated change on the future outlook of the industry, by taking into the account the political, economic, social, and technological parameters.

Somatropin is a recombinant human growth hormone indicated for the treatment of growth hormone deficiency in children and adults, as well as Turner syndrome, Prader-Willi syndrome, Chronic Renal Insufficiency (chronic kidney disorder), and others. Somatropin stimulates linear growth (height), tissue growth, and lipid, protein, carbohydrate, and mineral metabolism.

The global somatropin market is estimated to be valued at US$ 5.02 billion in 2020 and is expected to exhibit a CAGR of 7.9% during the forecast period (2020-2027).

Figure 1. Global Somatropin Market Share (%) in Terms of Value, By Region, 2019

Somatropin  | Coherent Market Insights

The increasing prevalence of growth hormone deficiency is expected to propel the market growth during the forecast period.

The increasing prevalence of growth hormone deficiency is expected to drive the global somatropin market growth during the forecast period. According to an article published in the Springer Nature journal in February 2017, the prevalence of growth hormone deficiency in children is within the range 1.8 to 2.9 per 10,000 in Europe and the U.S.

Figure 2. Global Somatropin Market Share (%), by Distribution Channel, 2020

Somatropin  | Coherent Market Insights

Increasing approvals of somatropin products by regulatory authorities is expected to drive the market growth during the forecast period

Approvals of various somatropin products by regulatory authorities such as the U.S. Food and Drug Administration (FDA) are expected to drive the market growth during the forecast period. For instance, in July 2018, Ferring Pharmaceuticals Inc. received approval from the U.S. Food and Drug Administration  for ZOMACTON, a somatropin injection, for the following additional pediatric indications:

  • Short stature due to Turner syndrome
  • Growth failure in short stature homeobox-containing gene (SHOX) deficiency
  • Idiopathic short stature (ISS)
  • Short stature born small for gestational age (SGA) with no catch-up growth by 2 to 4 years
request-sample

Global Somatropin Market Report Coverage

Report Coverage Details
Base Year: 2019 Market Size in 2019: US$ 5.02 Bn
Historical Data for: 2016 to 2019 Forecast Period: 2020 to 2027
Forecast Period 2020 to 2027 CAGR: 7.9% 2027 Value Projection: US$ 8.56 Bn
Geographies covered:
  • North America: U.S. and Canada
  • Latin America: Brazil, Argentina, Mexico, and Rest of Latin America
  • Europe: Germany, U.K., Spain, France, Italy, Russia, and Rest of Europe
  • Asia Pacific: China, India, Japan, Australia, South Korea, ASEAN, and Rest of Asia Pacific
  • Middle East: GCC Countries, Israel, and Rest of Middle East
  • Africa: South Africa, North Africa, and Central Africa
Segments covered:
  • By Dosage Form: Powder, Solvent.
  • By Application: Growth Hormone Deficiency (GHD), Turner Syndrome, Chronic Renal Insufficiency, Prader Willi Syndrome, Small for Gestational Age, SHOX Deficiency, Others.
  • By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies.
Companies covered:

Novo Nordisk A/S, Pfizer, Inc., Eli Lilly and Company, GeneScience Pharmaceuticals, Sandoz International, Ipsen Inc., LG Life Sciences, Merck KGaA, F. Hoffmann-La Roche, Teva Pharmaceutical Industries Ltd., and Ferring Pharmaceuticals

Growth Drivers:
  • The increasing prevalence of growth hormone deficiency
  • Approvals by regulatory authorities
Restraints & Challenges:
  • Development of alternate treatments

Global Somatropin Market – Impact of Coronavirus (Covid-19) Pandemic

The COVID-19 pandemic is affecting clinical trials drastically. According to a survey conducted by Medidata Solutions, Inc. (an American technology company which develops and markets software as a service for clinical trials), on April 23, 2020, 63% of survey respondents reported that they have stopped recruiting new patients for ongoing clinical trials and 43% of the respondents have postponed their studies.

Furthermore, ongoing clinical trials need to be conducted by healthcare facilities and researchers by adhering to the following safety measures:

  • Healthcare providers are obtaining patient consents through phone or video conferences. According to a survey conducted by Medidata Solutions, Inc., on April 23, 2020, 45% of the respondents opted for virtual/telemedicine for consultancy.
  • The patients receive a phone call for the screening of COVID-19 symptoms before the scheduled in-person visits.
  • Assessments of the studies are being done in single outpatient areas.

Global Somatropin Market: Restraint

Key players are focused on developing advanced alternative treatments for growth hormone deficiency, which is expected to hinder growth of the Europe somatropin market. For instance, in October 2019, OPKO Health Inc. and Pfizer Inc. announced the results of phase 3 clinical trial, which was initiated to evaluate the safety and efficacy of somatrogen, a long-acting human growth hormone (hGH) molecule administered once in a week in pre-pubertal children with growth hormone deficiency (GHD).

Key Players

Major players operating in global somatropin market are Novo Nordisk A/S, Pfizer, Inc., Eli Lilly and Company, GeneScience Pharmaceuticals, Sandoz International, Ipsen Inc., LG Life Sciences, Merck KGaA, F. Hoffmann-La Roche, Teva Pharmaceutical Industries Ltd., and Ferring Pharmaceuticals.

The increasing prevalence of growth hormone deficiency due to traumatic brain injuries is expected to propel the growth of the global somatropin market during the forecast period. According to an article published in the International Journal of Molecular Sciences in July 2019, growth hormone deficiency is the most common hormone deficiency in long term survivors of traumatic brain injury.

Market Dynamics

Market players are focusing on adopting various inorganic growth strategies such as agreements and acquisitions to strengthen their market presence and enhance their product portfolio. This is expected to drive growth of the global somatropin market during the forecast period. For instance, in October 2017, Ferring Pharmaceuticals entered a definitive agreement with Antares Pharma, Inc. to acquire the rights for the ZomaJet needle-free auto injector device.

Furthermore, research and development activities by key players are expected to propel the growth of global somatropin market during the forecast period. For instance, March 2017, GeneScience Pharmaceuticals Co., Ltd. initiated a phase 4 clinical trial to evaluate the safety and efficacy of PEG-Somatropin for the treatment of pediatric patients with growth hormone deficiency.

Key features of the study:

  • This report provides in-depth analysis of the global somatropin market, and provides market size (US$ Bn) and compound annual growth rate (CAGR%) for the forecast period (2020–2027), considering 2019 as the base year
  • It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
  • This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends,  regional outlook, and competitive strategies adopted by key players
  • It profiles key players in the global somatropin market based on the following parameters – company overview, financial performance, product portfolio, market presence, distribution strategies, key developments, strategies, and future plans
  • Key companies covered as a part of this study are Novo Nordisk A/S, Pfizer, Inc., Eli Lilly and Company, GeneScience Pharmaceuticals, Sandoz International, Ipsen Inc., LG Life Sciences, Merck KGaA, F. Hoffmann-La Roche, Teva Pharmaceutical Industries Ltd., and Ferring Pharmaceuticals
  • Insights from this report would allow marketers and management authorities of companies to make informed decisions regarding future product launches, market expansion, and marketing tactics
  • The global somatropin market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
  • Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global somatropin market.

Detailed Segmentation:

  • Global Somatropin Market, By Dosage Form:
    • Powder
    • Solvent
  • Global Somatropin Market, By Application:
    • Growth Hormone Deficiency (GHD)
    • Turner Syndrome  
    • Chronic Renal Insufficiency
    • Prader Willi Syndrome
    • Small for Gestational Age
    • SHOX Deficiency
    • Others
  • Global Somatropin Market, By Distribution Channel:
    • Hospital Pharmacies
    • Retail Pharmacies
    • Online Pharmacies
  • Global Somatropin Market, By Region:
    • North America
      • By Dosage Form:
        • Powder
        • Solvent
      • By Application
        • Growth Hormone Deficiency (GHD)
        • Turner Syndrome 
        • Chronic Renal Insufficiency
        • Prader Willi Syndrome
        • Small for Gestational Age
        • SHOX Deficiency
        • Others  
      • By Distribution Channel:
        • Hospital Pharmacies
        • Retail Pharmacies
        • Online Pharmacies
      • By Country:
        • U.S.
        • Canada
    • Latin America
      • By Dosage Form:
        • Powder
        • Solvent
      • By Application
        • Growth Hormone Deficiency (GHD)
        • Turner Syndrome 
        • Chronic Renal Insufficiency
        • Prader Willi Syndrome
        • Small for Gestational Age
        • SHOX Deficiency
        • Others 
      • By Distribution Channel:
        • Hospital Pharmacies
        • Retail Pharmacies
        • Online Pharmacies
      • By Country:
        • Brazil
        • Mexico
        • Argentina
        • Rest of Latin America
    • Europe
      • By Dosage Form:
        • Powder
        • Solvent
      • By Application
        • Growth Hormone Deficiency (GHD)
        • Turner Syndrome 
        • Chronic Renal Insufficiency
        • Prader Willi Syndrome
        • Small for Gestational Age
        • SHOX Deficiency
        • Others 
      • By Distribution Channel:
        • Hospital Pharmacies
        • Retail Pharmacies
        • Online Pharmacies
      • By Country:
        • Germany
        • U.K.
        • France
        • Italy
        • Spain
        • Russia
        • Rest of Europe
    • Asia Pacific
      • By Dosage Form:
        • Powder
        • Solvent
      • By Application
        • Growth Hormone Deficiency (GHD)
        • Turner Syndrome 
        • Chronic Renal Insufficiency
        • Prader Willi Syndrome
        • Small for Gestational Age
        • SHOX Deficiency
        • Others 
      • By Distribution Channel:
        • Hospital Pharmacies
        • Retail Pharmacies
        • Online Pharmacies
      • By Country:
        • China
        • India
        • Japan
        • Australia
        • South Korea
        • ASEAN
        • Rest of Asia Pacific
    • Middle East
      • By Dosage Form:
        • Powder
        • Solvent
      • By Application
        • Growth Hormone Deficiency (GHD)
        • Turner Syndrome 
        • Chronic Renal Insufficiency
        • Prader Willi Syndrome
        • Small for Gestational Age
        • SHOX Deficiency
        • Others 
      • By Distribution Channel:
        • Hospital Pharmacies
        • Retail Pharmacies
        • Online Pharmacies
      • By Country:
        • GCC
        • Israel
        • Rest of Middle East
    • Africa
      • By Dosage Form:
        • Powder
        • Solvent
      • By Application
        • Growth Hormone Deficiency (GHD)
        • Turner Syndrome 
        • Chronic Renal Insufficiency
        • Prader Willi Syndrome
        • Small for Gestational Age
        • SHOX Deficiency
        • Others 
      • By Distribution Channel:
        • Hospital Pharmacies
        • Retail Pharmacies
        • Online Pharmacies
      • By Country/Region:
        • South Africa
        • Central Africa
        • North Africa
  • Company Profiles
    • Novo Nordisk A/S*
      • Company Overview
      • Material Portfolio
      • Financial Performance
      • Key Highlights
      • Market Strategies
    • Pfizer, Inc.
    • Eli Lilly and Company
    • GeneScience Pharmaceuticals
    • Sandoz International
    • Ipsen Inc.
    • LG Life Sciences
    • Merck KGaA
    • Hoffmann-La Roche
    • Teva Pharmaceutical Industries Ltd.
    • Ferring Pharmaceuticals

“*” marked represents similar segmentation in other categories in the respective section.

Table of Contents

  1. Research Objectives and Assumptions
    • Research Objectives
    • Assumptions
    • Abbreviations
  2. Market Purview
    • Report Description
      • Market Definition and Scope
    • Executive Summary
      • Market Snippet, By Dosage Form
      • Market Snippet, By Application
      • Market Snippet, By Distribution Channel
      • Market Snippet, By Region
    • Coherent Opportunity Map (COM)
  3. Market Dynamics, Regulations, and Trends Analysis
    • Market Dynamics
      • Drivers
      • Restraints
      • Market Opportunities
    • Impact Analysis
    • Key Developments
    • PEST Analysis
  4. Global Somatropin Market – Impact of Coronavirus (Covid-19) Pandemic
    • Impact assessment
    • Pre COVID-19 Market Scenario
    • Post COVID-19 Market Scenario
    • Government measures to combat COVID-19
  5. Global Somatropin Market, By Dosage Form, 2016 – 2027, (US$ Bn)
    • Introduction
      • Market Share Analysis, 2020 and 2027 (%)
      • Y-o-Y Growth Analysis, 2017 – 2027
      • Segment Trends
    • Powder
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Bn)
    • Solvent
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Bn)
  6. Global Somatropin Market, By Application, 2016 – 2027, (US$ Bn)
    • Introduction
      • Market Share Analysis, 2020 and 2027 (%)
      • Y-o-Y Growth Analysis, 2017 – 2027
      • Segment Trends
    • Growth Hormone Deficiency (GHD)
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Bn)
    • Turner Syndrome  
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Bn)
    • Chronic Renal Insufficiency
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Bn)
    • Prader Willi Syndrome
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Bn)
    • Small for Gestational Age
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Bn)
    • SHOX Deficiency
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Bn)
    • Others
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Bn)
  7. Global Somatropin Market, By Distribution Channel, 2016 – 2027, (US$ Bn)
    • Introduction
      • Market Share Analysis, 2020 and 2027 (%)
      • Y-o-Y Growth Analysis, 2017 – 2027
      • Segment Trends
    • Hospital Pharmacies
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Bn)
    • Retail Pharmacies
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Bn)
    • Online Pharmacies
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Bn)
  8. Global Somatropin Market, By Region, 2016 – 2027, (US$ Bn)
    • Introduction
      • Market Share Analysis, By Region, 2020 and 2027 (%)
      • Y-o-Y Growth Analysis, For Regions, 2017–2027
    • North America
      • Market Size and Forecast, By Dosage Form, 2016 – 2027, (US$ Bn)
      • Market Size and Forecast, By Application, 2016 – 2027, (US$ Bn)
      • Market Size and Forecast, By Distribution Channel, 2016 – 2027, (US$ Bn)
      • Market Size and Forecast, By Country, 2016 – 2027, (US$ Bn)
        • U.S.
        • Canada
    • Latin America
      • Market Size and Forecast, By Dosage Form, 2016 – 2027, (US$ Bn)
      • Market Size and Forecast, By Application, 2016 – 2027, (US$ Bn)
      • Market Size and Forecast, By Distribution Channel, 2016 – 2027, (US$ Bn)
      • Market Size and Forecast, By Country, 2016 – 2027, (US$ Bn)
        • Brazil
        • Mexico
        • Argentina
        • Rest of Latin America
    • Europe
      • Market Size and Forecast, By Dosage Form, 2016 – 2027, (US$ Bn)
      • Market Size and Forecast, By Application, 2016 – 2027, (US$ Bn)
      • Market Size and Forecast, By Distribution Channel, 2016 – 2027, (US$ Bn)
      • Market Size and Forecast, By Country, 2016 – 2027, (US$ Bn)
        • Germany
        • U.K.
        • France
        • Italy
        • Spain
        • Russia
        • Rest of Europe
    • Asia Pacific
      • Market Size and Forecast, By Dosage Form, 2016 – 2027, (US$ Bn)
      • Market Size and Forecast, By Application, 2016 – 2027, (US$ Bn)
      • Market Size and Forecast, By Distribution Channel, 2016 – 2027, (US$ Bn)
      • Market Size and Forecast, By Country, 2016 – 2027, (US$ Bn)
        • China
        • India
        • Japan
        • Australia
        • South Korea
        • ASEAN
        • Rest of Asia Pacific
    • Middle East
      • Market Size and Forecast, By Dosage Form, 2016 – 2027, (US$ Bn)
      • Market Size and Forecast, By Application, 2016 – 2027, (US$ Bn)
      • Market Size and Forecast, By Distribution Channel, 2016 – 2027, (US$ Bn)
      • Market Size and Forecast, By Country, 2016 – 2027, (US$ Bn)
        • GCC
        • Israel
        • Rest of Middle East
    • Africa
      • Market Size and Forecast, By Dosage Form, 2016 – 2027, (US$ Bn)
      • Market Size and Forecast, By Application, 2016 – 2027, (US$ Bn)
      • Market Size and Forecast, By Distribution Channel, 2016 – 2027, (US$ Bn)
      • Market Size and Forecast, By Country/Region, 2016 – 2027, (US$ Bn)
        • South Africa
        • Central Africa
        • North Africa
  9. Competitive Landscape
    • Heat Map Analysis
    • Market Share Analysis
      • Novo Nordisk A/S
        • Company Overview
        • Device Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • Pfizer, Inc.
        • Company Overview
        • Device Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • Eli Lilly and Company
        • Company Overview
        • Device Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • GeneScience Pharmaceuticals
        • Company Overview
        • Device Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • Sandoz International
        • Company Overview
        • Device Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • Ipsen Inc.
        • Company Overview
        • Device Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • LG Life Sciences
        • Company Overview
        • Device Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • Merck KGaA
        • Company Overview
        • Device Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • Hoffmann-La Roche
        • Company Overview
        • Device Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • Teva Pharmaceutical Industries Ltd.
        • Company Overview
        • Device Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • Ferring Pharmaceuticals
        • Company Overview
        • Device Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
    • Analyst Views
  10. Section
    • References
    • Research Methodology
    • About us and Sales Contact

*Browse 27 market data tables and 26 figures on "Somatropin Market” - Global forecast to 2027

Frequently Asked Questions

The global somatropin market size is estimated to be valued at US$ 5.02 billion in 2020 and is expected to exhibit a CAGR of 7.9% between 2020 and 2027.
The increasing prevalence of growth hormone deficiency, and approvals of somatropin products by regulatory authorities are driving the somatropin market growth.
The solvent segment is expected to hold major market share owing to product approvals and launches during the forecast period.
North America somatropin market is expected to generate highest revenue share.
Major factor hampering growth of the market include development of alternative treatments for growth hormone deficiency.
Major players operating in the global somatropin market are Novo Nordisk A/S, Pfizer, Inc., Eli Lilly and Company, GeneScience Pharmaceuticals, and others.
Existing Clientele

Joining thousands of companies around the world committed to making the Excellent Business Solutions.

View All Our Clients

Our Trusted Patner